Inclusion Criteria:

Postmenopausal as defined by NCCN (any of the following)

- Prior bilateral oophorectomy

- Age equal to or greater then 60 years of age

- Age less then 60 and amenorrheic for 12 or more months in the absence of
chemotherapy, tamoxifen, toremifen or ovarian suppression and FSH and estradiol in
the postmenopausal range

- If taking tamoxifen or toremifen and age less then 60y, then FSH and plasma estradiol
level in postmenopausal ranges

Informed consent- Individuals capable of consenting and self administering the survey
instrument Dentate- At least 15 teeth present.

AI users:

- Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with
no evidence of metastatic disease.

- Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or
letrozole) > 1 month. Subjects may have had prior tamoxifen or raloxifene. Subjects
may have had chemotherapy and/or radiation therapy. Must be within the first year of
consecutive AI therapy. If a subject started AI, discontinued, then restarted, they
will be accepted into the study.

Controls:

- No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not
including a history of localized thyroid or skin cancer).

Exclusion Criteria:

Medical history

- Metastatic BCa (AI treated group: fully resected locally recurrent disease is
permitted if the patient has been rendered without evidence of disease).

- Significant psychiatric illness/social situations that would preclude completion of
questionnaire.

Medications

- Chronic medications known to affect the periodontal status (calcium antagonist,
anti-convulsives, immunosuppressives (> prednisone 7.5mg daily). NSAIDS and
bisphosphonates are permitted.

- Premedication- Conditions that require antibiotic therapy will be evaluated on a
case-by-case basis. (Patients taking prophylaxis for joint replacements will not be
excluded.)